Product Description
Mechanisms of Action: COMT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | France | Germany | Greece | Hong Kong | Hungary | India | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sri Lanka | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: ALIO MEDICA Sp. z o.o.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Varicose Veins|Chronic Pain|Pelvic Pain|Forearm Injuries|Venous Thrombosis|Postthrombotic Syndrome|Edema|Venous Insufficiency|Postphlebitic Syndrome|Rectal Fistula|Lymphedema|Anal Fistula
Phase 3: Peptic Ulcer|Hemorrhoids|Ovarian Hyperstimulation Syndrome|Infertility|Lipodystrophy|Cellulite|Venous Insufficiency|Edema|Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Chronic Pain|Leukocyte Disorders|Kidney Diseases|Bile Reflux|Vaginal Diseases|Common Bile Duct Diseases|Colitis, Ulcerative|Arthritis, Rheumatoid|Ovarian Diseases|Uterine Diseases|Inflammation|Pelvic Pain|Hypertension, Renal|Depressive Disorder|Abdominal Pain|Varicose Veins
Phase 1: Coronavirus Infections|Acute Respiratory Distress Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
RyazanSMU | N/A |
Active, not recruiting |
Varicose Veins|Edema |
2026-04-01 |
|
N202309013 | P4 |
Recruiting |
Rectal Fistula|Anal Fistula |
2025-12-31 |
|
NCT05756179 | P3 |
Recruiting |
Arthritis, Rheumatoid |
2025-09-01 |
|
PVDUS-01 | N/A |
Not yet recruiting |
Scleroderma, Diffuse|Skin Ulcer|Scleroderma, General|Scleroderma, Systemic |
2025-07-15 |